At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from open-heart surgery to balloon valvuloplasty. What can I do to help the ...

At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from open-heart surgery to balloon valvuloplasty. What can I do to help the ...

Edwards Lifesciences stock is supported by its growth outlook and the impact of clinical advances. See why investors should ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making ...

Irvine, California Friday, December 26, 2025, 11:00 Hrs [IST] ...

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

Transcatheter heart valve repair and replacement have reshaped how structural heart disease is treated, and the market is evolving just as quickly.

A NEW analysis reveals that transcatheter mitral valve replacement delivers sustained benefits for patients with high-risk mitral regurgitation, demonstrating long term stability and improved symptoms ...

Edwards’ Pascal and Abbott’s MitraClip TEER devices are cleared in the U.S. to repair the mitral valve in patients with mitral regurgitation. The condition occurs when the valve does not shut properly ...

Mitral valve regurgitation is a heart condition that occurs when the mitral valve does not close properly, allowing blood to flow backward into the left atrium. Symptoms do not always occur. When they ...